10/30/2014 - 11:45 AM EST - Critical Outcome Technologies Inc. : announced today that its lead oncology drug candidate, COTI-2, successfully completed two-species repeated dose toxicity studies in anticipation of a United States Food and Drug Administration Investigational New Drug filing. Critical Outcome Technologies Inc.
shares V.COT are trading down $0.015 at $0.24.
